Biocorp Production: management transactions · France · AMF

About Biocorp Production

BIOCORP PRODUCTION is a French company specializing in the design and manufacture of medical devices and innovative drug-delivery systems. Originally established in 2004 in Issoire, near Clermont-Ferrand, the company grew out of a family industrial background and built its business on a combination of precision plastics engineering, medical-device know-how, and connected technologies. BIOCORP emphasizes an integrated operating model, controlling the full value chain from research and development through production and final packaging, which supports product quality, customization, and faster innovation cycles. The group first developed a portfolio of conventional drug-delivery devices and later expanded into connected solutions and smart accessories aimed at improving treatment adherence and patient experience. Its product range has included traditional delivery systems, connected injection systems, monitoring devices, and add-ons that can be adapted to existing injection pens on the market. This positioning has made BIOCORP a niche player in medical plastics and injectable drug-delivery technologies, with a focus on chronic diseases and on solutions that can integrate data collection and digital connectivity into everyday treatment routines. From an industrial standpoint, BIOCORP operates two complementary French sites. The Clermont-Ferrand location hosts development, innovation, and support functions, while the Issoire site is dedicated to production and quality. The company states that it employs 105 people across these sites, underscoring a mid-sized, agile operating structure. This local manufacturing footprint in France is strategically important for quality control, supply-chain responsiveness, and the ability to move quickly from design to industrial scale-up, especially for medical-device customers requiring high reliability and regulatory discipline. BIOCORP was listed on Alternext in July 2015 under ISIN FR0012788065. A key recent milestone was Novo Nordisk’s acquisition of a controlling stake, completed on August 4, 2023, after the Danish healthcare group bought 64.3% of BIOCORP’s share capital at EUR 35.00 per share. That transaction materially changed BIOCORP’s ownership profile and anchored the company within the ecosystem of one of the world’s leading diabetes-focused healthcare groups, which is highly relevant given BIOCORP’s expertise in injectable delivery devices and connected treatment solutions.